-
1
-
-
0037010474
-
Comparative Risk Assessment Collaborating G. Selected major risk factors and global and regional burden of disease
-
Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Comparative Risk Assessment Collaborating G. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-1360.
-
(2002)
Lancet
, vol.360
, pp. 1347-1360
-
-
Ezzati, M.1
Lopez, A.D.2
Rodgers, A.3
Vander Hoorn, S.4
Murray, C.J.5
-
2
-
-
34547615709
-
The task force for the management of arterial hypertension of the European Society of H, the task force for the management of arterial hypertension of the European Society of C. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
-
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Manolis A, Nilsson PM, Redon J, Struijker-Boudier HA, Viigimaa M, Adamopoulos S, Bertomeu V, Clement D, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, O'Brien E, Ponikowski P, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B. The task force for the management of arterial hypertension of the European Society of H, The task force for the management of arterial hypertension of the European Society of C. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28: 1462-1536.
-
(2007)
Eur Heart J
, vol.28
, pp. 1462-1536
-
-
Mancia, G.1
De Backer, G.2
Dominiczak, A.3
Cifkova, R.4
Fagard, R.5
Germano, G.6
Grassi, G.7
Heagerty, A.M.8
Kjeldsen, S.E.9
Laurent, S.10
Narkiewicz, K.11
Ruilope, L.12
Rynkiewicz, A.13
Schmieder, R.E.14
Struijker Boudier, H.A.15
Zanchetti, A.16
Vahanian, A.17
Camm, J.18
De Caterina, R.19
Dean, V.20
Dickstein, K.21
Filippatos, G.22
Funck-Brentano, C.23
Hellemans, I.24
Kristensen, S.D.25
McGregor, K.26
Sechtem, U.27
Silber, S.28
Tendera, M.29
Widimsky, P.30
Zamorano, J.L.31
Erdine, S.32
Kiowski, W.33
Agabiti-Rosei, E.34
Ambrosioni, E.35
Lindholm, L.H.36
Manolis, A.37
Nilsson, P.M.38
Redon, J.39
Struijker-Boudier, H.A.40
Viigimaa, M.41
Adamopoulos, S.42
Bertomeu, V.43
Clement, D.44
Farsang, C.45
Gaita, D.46
Lip, G.47
Mallion, J.M.48
Manolis, A.J.49
O'Brien, E.50
Ponikowski, P.51
Ruschitzka, F.52
Tamargo, J.53
Van Zwieten, P.54
Waeber, B.55
Williams, B.56
more..
-
3
-
-
0347423198
-
National Heart L, Blood I, National High Blood Pressure Education Program Coordinating C. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
-
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Joint National Committee on Prevention DE, Treatment of High Blood Pressure. National Heart L, Blood I, National High Blood Pressure Education Program Coordinating C. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42: 1206-1252.
-
(2003)
Hypertension
, vol.42
, pp. 1206-1252
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
Cushman, W.C.4
Green, L.A.5
Izzo, Jr.J.L.6
Jones, D.W.7
Materson, B.J.8
Oparil, S.9
Wright, Jr.J.T.10
Roccella, E.11
-
4
-
-
0017319491
-
The biochemistry of the renin-angiotensin system and its role in hypertension
-
Skeggs LT, Dorer FE, Kahn JR, Lentz KE, Levine M. The biochemistry of the renin-angiotensin system and its role in hypertension. Am J Med 1976;60: 737-748.
-
(1976)
Am J Med
, vol.60
, pp. 737-748
-
-
Skeggs, L.T.1
Dorer, F.E.2
Kahn, J.R.3
Lentz, K.E.4
Levine, M.5
-
5
-
-
77951136034
-
Cardioprotective effects of a selective B(2) receptor agonist of bradykinin post-acute myocardial infarct
-
Marketou M, Kintsurashvili E, Papanicolaou KN, Lucero HA, Gavras I, Gavras H. Cardioprotective effects of a selective B(2) receptor agonist of bradykinin post-acute myocardial infarct. Am J Hypertens 2010;23:562-568.
-
(2010)
Am J Hypertens
, vol.23
, pp. 562-568
-
-
Marketou, M.1
Kintsurashvili, E.2
Papanicolaou, K.N.3
Lucero, H.A.4
Gavras, I.5
Gavras, H.6
-
6
-
-
0025913812
-
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators
-
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
-
(1991)
N Engl J Med
, vol.325
, pp. 293-302
-
-
-
7
-
-
0034688194
-
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
-
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
-
(2000)
N Engl J Med
, vol.342
, pp. 145-153
-
-
Yusuf, S.1
Sleight, P.2
Pogue, J.3
Bosch, J.4
Davies, R.5
Dagenais, G.6
-
8
-
-
0042330455
-
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
-
Fox KM, Investigators EUtOrocewPiscAd. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
-
(2003)
Lancet
, vol.362
, pp. 782-788
-
-
Fox, K.M.1
-
9
-
-
0035922441
-
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
-
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, Investigators RS. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
-
(2001)
N Engl J Med
, vol.345
, pp. 861-869
-
-
Brenner, B.M.1
Cooper, M.E.2
De Zeeuw, D.3
Keane, W.F.4
Mitch, W.E.5
Parving, H.H.6
Remuzzi, G.7
Snapinn, S.M.8
Zhang, Z.9
Shahinfar, S.10
Investigators, R.S.11
-
10
-
-
77951453096
-
Effect of valsartan on the incidence of diabetes and cardiovascular events
-
Group NS, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamas G, Tognoni G, Tuomilehto J, Villamil AS, Vozar J, Califf RM. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-1490.
-
(2010)
N Engl J Med
, vol.362
, pp. 1477-1490
-
-
Group, N.S.1
McMurray, J.J.2
Holman, R.R.3
Haffner, S.M.4
Bethel, M.A.5
Holzhauer, B.6
Hua, T.A.7
Belenkov, Y.8
Boolell, M.9
Buse, J.B.10
Buckley, B.M.11
Chacra, A.R.12
Chiang, F.T.13
Charbonnel, B.14
Chow, C.C.15
Davies, M.J.16
Deedwania, P.17
Diem, P.18
Einhorn, D.19
Fonseca, V.20
Fulcher, G.R.21
Gaciong, Z.22
Gaztambide, S.23
Giles, T.24
Horton, E.25
Ilkova, H.26
Jenssen, T.27
Kahn, S.E.28
Krum, H.29
Laakso, M.30
Leiter, L.A.31
Levitt, N.S.32
Mareev, V.33
Martinez, F.34
Masson, C.35
Mazzone, T.36
Meaney, E.37
Nesto, R.38
Pan, C.39
Prager, R.40
Raptis, S.A.41
Rutten, G.E.42
Sandstroem, H.43
Schaper, F.44
Scheen, A.45
Schmitz, O.46
Sinay, I.47
Soska, V.48
Stender, S.49
Tamas, G.50
Tognoni, G.51
Tuomilehto, J.52
Villamil, A.S.53
Vozar, J.54
Califf, R.M.55
more..
-
11
-
-
34247379373
-
Jikei Heart Study g. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomised, open-label, blinded endpoint morbidity-mortality study
-
Mochizuki S, Dahlof B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N, Jikei Heart Study g. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431-1439.
-
(2007)
Lancet
, vol.369
, pp. 1431-1439
-
-
Mochizuki, S.1
Dahlof, B.2
Shimizu, M.3
Ikewaki, K.4
Yoshikawa, M.5
Taniguchi, I.6
Ohta, M.7
Yamada, T.8
Ogawa, K.9
Kanae, K.10
Kawai, M.11
Seki, S.12
Okazaki, F.13
Taniguchi, M.14
Yoshida, S.15
Tajima, N.16
-
12
-
-
57349142933
-
Irbe-sartan in patients with heart failure and preserved ejection fraction
-
Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, Investigators IP. Irbe-sartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-2467.
-
(2008)
N Engl J Med
, vol.359
, pp. 2456-2467
-
-
Massie, B.M.1
Carson, P.E.2
McMurray, J.J.3
Komajda, M.4
McKelvie, R.5
Zile, M.R.6
Anderson, S.7
Donovan, M.8
Iverson, E.9
Staiger, C.10
Ptaszynska, A.11
-
13
-
-
0042410539
-
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme
-
Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, Investigators C. Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-766.
-
(2003)
Lancet
, vol.362
, pp. 759-766
-
-
Pfeffer, M.A.1
Swedberg, K.2
Granger, C.B.3
Held, P.4
McMurray, J.J.5
Michelson, E.L.6
Olofsson, B.7
Ostergren, J.8
Yusuf, S.9
Pocock, S.10
-
14
-
-
57349138291
-
Benazepril plus amlodipine or hydro-chlorothiazide for hypertension in high-risk patients
-
Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, Investigators AT. Benazepril plus amlodipine or hydro-chlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359: 2417-2428.
-
(2008)
N Engl J Med
, vol.359
, pp. 2417-2428
-
-
Jamerson, K.1
Weber, M.A.2
Bakris, G.L.3
Dahlof, B.4
Pitt, B.5
Shi, V.6
Hester, A.7
Gupte, J.8
Gatlin, M.9
Velazquez, E.J.10
-
15
-
-
42049107348
-
Telmisartan, ramipril, or both in patients at high risk for vascular events
-
Investigators O, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559.
-
(2008)
N Engl J Med
, vol.358
, pp. 1547-1559
-
-
Yusuf, S.1
Teo, K.K.2
Pogue, J.3
Dyal, L.4
Copland, I.5
Schumacher, H.6
Dagenais, G.7
Sleight, P.8
Anderson, C.9
-
16
-
-
0345492460
-
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial
-
Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW, Investigators I. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-2816.
-
(2003)
JAMA
, vol.290
, pp. 2805-2816
-
-
Pepine, C.J.1
Handberg, E.M.2
Cooper-Dehoff, R.M.3
Marks, R.G.4
Kowey, P.5
Messerli, F.H.6
Mancia, G.7
Cangiano, J.L.8
Garcia-Barreto, D.9
Keltai, M.10
Erdine, S.11
Bristol, H.A.12
Kolb, H.R.13
Bakris, G.L.14
Cohen, J.D.15
Parmley, W.W.16
-
18
-
-
0030922816
-
Bias in meta-analysis detected by a simple, graphical test
-
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
-
(1997)
BMJ
, vol.315
, pp. 629-634
-
-
Egger, M.1
Davey Smith, G.2
Schneider, M.3
Minder, C.4
-
19
-
-
66249127233
-
Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE)
-
Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa H, Investigators H-C. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009;30: 1203-1212.
-
(2009)
Eur Heart J
, vol.30
, pp. 1203-1212
-
-
Kasanuki, H.1
Hagiwara, N.2
Hosoda, S.3
Sumiyoshi, T.4
Honda, T.5
Haze, K.6
Nagashima, M.7
Yamaguchi, J.8
Origasa, H.9
Urashima, M.10
Ogawa, H.11
-
20
-
-
55349147316
-
Group C-JT. ARB candesartan and CCB amlodipine in hypertensive patients: The CASE-J trial
-
Ogihara T, Fujimoto A, Nakao K, Saruta T, Group C-JT. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther 2008;6:1195-1201.
-
(2008)
Expert Rev Cardiovasc Ther
, vol.6
, pp. 1195-1201
-
-
Ogihara, T.1
Fujimoto, A.2
Nakao, K.3
Saruta, T.4
-
21
-
-
73849084830
-
Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study
-
Sawada T, Yamada H, Dahlof B, Matsubara H, Group KHS. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009;30:2461-2469.
-
(2009)
Eur Heart J
, vol.30
, pp. 2461-2469
-
-
Sawada, T.1
Yamada, H.2
Dahlof, B.3
Matsubara, H.4
-
22
-
-
52249116778
-
Telmisartan to prevent recurrent stroke and cardiovascular events
-
Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW, Group PRS. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359: 1225-1237.
-
(2008)
N Engl J Med
, vol.359
, pp. 1225-1237
-
-
Yusuf, S.1
Diener, H.C.2
Sacco, R.L.3
Cotton, D.4
Ounpuu, S.5
Lawton, W.A.6
Palesch, Y.7
Martin, R.H.8
Albers, G.W.9
Bath, P.10
Bornstein, N.11
Chan, B.P.12
Chen, S.T.13
Cunha, L.14
Dahlof, B.15
De Keyser, J.16
Donnan, G.A.17
Estol, C.18
Gorelick, P.19
Gu, V.20
Hermansson, K.21
Hilbrich, L.22
Kaste, M.23
Lu, C.24
MacHnig, T.25
Pais, P.26
Roberts, R.27
Skvortsova, V.28
Teal, P.29
Toni, D.30
Vandermaelen, C.31
Voigt, T.32
Weber, M.33
Yoon, B.W.34
more..
-
23
-
-
42949112210
-
Treatment of hypertension in patients 80 years of age or older
-
Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, Group HS. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898.
-
(2008)
N Engl J Med
, vol.358
, pp. 1887-1898
-
-
Beckett, N.S.1
Peters, R.2
Fletcher, A.E.3
Staessen, J.A.4
Liu, L.5
Dumitrascu, D.6
Stoyanovsky, V.7
Antikainen, R.L.8
Nikitin, Y.9
Anderson, C.10
Belhani, A.11
Forette, F.12
Rajkumar, C.13
Thijs, L.14
Banya, W.15
Bulpitt, C.J.16
Group, H.S.17
-
24
-
-
10744233011
-
Hypertension in the Very Elderly Trial Working G. Results of the pilot study for the Hypertension in the Very Elderly Trial
-
Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C, Nunes M, Peters R, Staessen JA, Thijs L, Hypertension in the Very Elderly Trial Working G. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003;21:2409-2417.
-
(2003)
J Hypertens
, vol.21
, pp. 2409-2417
-
-
Bulpitt, C.J.1
Beckett, N.S.2
Cooke, J.3
Dumitrascu, D.L.4
Gil-Extremera, B.5
Nachev, C.6
Nunes, M.7
Peters, R.8
Staessen, J.A.9
Thijs, L.10
-
25
-
-
0037160968
-
Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
-
Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Group LS. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
-
(2002)
Lancet
, vol.359
, pp. 995-1003
-
-
Dahlof, B.1
Devereux, R.B.2
Kjeldsen, S.E.3
Julius, S.4
Beevers, G.5
De Faire, U.6
Fyhrquist, F.7
Ibsen, H.8
Kristiansson, K.9
Lederballe-Pedersen, O.10
Lindholm, L.H.11
Nieminen, M.S.12
Omvik, P.13
Oparil, S.14
Wedel, H.15
Group, L.S.16
-
26
-
-
24644443331
-
Prevention of cardiovascular events with an antihy-pertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial
-
Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Investigators A. Prevention of cardiovascular events with an antihy-pertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
-
(2005)
Lancet
, vol.366
, pp. 895-906
-
-
Dahlof, B.1
Sever, P.S.2
Poulter, N.R.3
Wedel, H.4
Beevers, D.G.5
Caulfield, M.6
Collins, R.7
Kjeldsen, S.E.8
Kristinsson, A.9
McInnes, G.T.10
Mehlsen, J.11
Nieminen, M.12
O'Brien, E.13
Ostergren, J.14
Investigators, A.15
-
27
-
-
2942635317
-
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
-
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, group Vt. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363: 2022-2031.
-
(2004)
Lancet
, vol.363
, pp. 2022-2031
-
-
Julius, S.1
Kjeldsen, S.E.2
Weber, M.3
Brunner, H.R.4
Ekman, S.5
Hansson, L.6
Hua, T.7
Laragh, J.8
McInnes, G.T.9
Mitchell, L.10
Plat, F.11
Schork, A.12
Smith, B.13
Zanchetti, A.14
Group, V.T.15
-
28
-
-
0035922447
-
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
-
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study G. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
-
(2001)
N Engl J Med
, vol.345
, pp. 851-860
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Clarke, W.R.3
Berl, T.4
Pohl, M.A.5
Lewis, J.B.6
Ritz, E.7
Atkins, R.C.8
Rohde, R.9
Raz, I.10
-
29
-
-
0037534905
-
The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial
-
Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A, Group SS. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886.
-
(2003)
J Hypertens
, vol.21
, pp. 875-886
-
-
Lithell, H.1
Hansson, L.2
Skoog, I.3
Elmfeldt, D.4
Hofman, A.5
Olofsson, B.6
Trenkwalder, P.7
Zanchetti, A.8
-
30
-
-
0001667151
-
Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
-
Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
-
(2002)
JAMA
, vol.288
, pp. 2981-2997
-
-
Officers, A.1
-
31
-
-
34548420712
-
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial
-
Patel A, Group AC, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840.
-
(2007)
Lancet
, vol.370
, pp. 829-840
-
-
Patel, A.1
Group, A.C.2
MacMahon, S.3
Chalmers, J.4
Neal, B.5
Woodward, M.6
Billot, L.7
Harrap, S.8
Poulter, N.9
Marre, M.10
Cooper, M.11
Glasziou, P.12
Grobbee, D.E.13
Hamet, P.14
Heller, S.15
Liu, L.S.16
Mancia, G.17
Mogensen, C.E.18
Pan, C.Y.19
Rodgers, A.20
Williams, B.21
more..
-
32
-
-
20444427156
-
Morbidity and Mortality after Stroke, Epro-sartan Compared with Nitrendipine for Secondary Prevention: Principal results of a prospective randomized controlled study (MOSES)
-
Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, Group MS. Morbidity and Mortality After Stroke, Epro-sartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-1226.
-
(2005)
Stroke
, vol.36
, pp. 1218-1226
-
-
Schrader, J.1
Luders, S.2
Kulschewski, A.3
Hammersen, F.4
Plate, K.5
Berger, J.6
Zidek, W.7
Dominiak, P.8
Diener, H.C.9
Group, M.S.10
-
33
-
-
0037434556
-
Second Australian National Blood Pressure Study G. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly
-
Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ. Second Australian National Blood Pressure Study G. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-592.
-
(2003)
N Engl J Med
, vol.348
, pp. 583-592
-
-
Wing, L.M.1
Reid, C.M.2
Ryan, P.3
Beilin, L.J.4
Brown, M.A.5
Jennings, G.L.6
Johnston, C.I.7
McNeil, J.J.8
MacDonald, G.J.9
Marley, J.E.10
Morgan, T.O.11
West, M.J.12
-
34
-
-
11144355108
-
Japan Multicenter Investigation for Cardiovascular Diseases BSG. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: The Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial
-
Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S, Kawai C, Japan Multicenter Investigation for Cardiovascular Diseases BSG. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004;27:181-191.
-
(2004)
Hypertens Res
, vol.27
, pp. 181-191
-
-
Yui, Y.1
Sumiyoshi, T.2
Kodama, K.3
Hirayama, A.4
Nonogi, H.5
Kanmatsuse, K.6
Origasa, H.7
Iimura, O.8
Ishii, M.9
Saruta, T.10
Arakawa, K.11
Hosoda, S.12
Kawai, C.13
-
35
-
-
53049109468
-
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial
-
Telmisartan Randomised AssessmeNt Study in ACEiswc DI, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-1183.
-
(2008)
Lancet
, vol.372
, pp. 1174-1183
-
-
Eiswc, D.I.1
Yusuf, S.2
Teo, K.3
Anderson, C.4
Pogue, J.5
Dyal, L.6
Copland, I.7
Schumacher, H.8
Dagenais, G.9
Sleight, P.10
-
36
-
-
33746863179
-
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: A combined analysis of three trials
-
Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368:581-588.
-
(2006)
Lancet
, vol.368
, pp. 581-588
-
-
Dagenais, G.R.1
Pogue, J.2
Fox, K.3
Simoons, M.L.4
Yusuf, S.5
-
37
-
-
79952213953
-
Antihyper-tensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: A meta-analysis
-
Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihyper-tensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 2011;305:913-922.
-
(2011)
JAMA
, vol.305
, pp. 913-922
-
-
Thompson, A.M.1
Hu, T.2
Eshelbrenner, C.L.3
Reynolds, K.4
He, J.5
Bazzano, L.A.6
-
38
-
-
67650082354
-
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
-
Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
-
(2009)
BMJ
, vol.338
-
-
Law, M.R.1
Morris, J.K.2
Wald, N.J.3
-
39
-
-
33745295923
-
Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
-
Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-893.
-
(2006)
Ann Intern Med
, vol.144
, pp. 884-893
-
-
Messerli, F.H.1
Mancia, G.2
Conti, C.R.3
Hewkin, A.C.4
Kupfer, S.5
Champion, A.6
Kolloch, R.7
Benetos, A.8
Pepine, C.J.9
-
40
-
-
33747767282
-
Angiotensin receptor blockers may increase risk of myocar-dial infarction: Unraveling the ARB-MI paradox
-
Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocar-dial infarction: unraveling the ARB-MI paradox. Circulation 2006;114:838-854.
-
(2006)
Circulation
, vol.114
, pp. 838-854
-
-
Strauss, M.H.1
Hall, A.S.2
-
41
-
-
79955667530
-
Angiotensin receptor blockers and risk of myocardial infarction: Meta-analyses and trial sequential analyses of 147 020 patients from randomised trials
-
Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011;342:d2234.
-
(2011)
BMJ
, vol.342
-
-
Bangalore, S.1
Kumar, S.2
Wetterslev, J.3
Messerli, F.H.4
-
42
-
-
34147116836
-
Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system
-
Blood Pressure Lowering Treatment, Trialists C, Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007;25:951-958.
-
(2007)
J Hypertens
, vol.25
, pp. 951-958
-
-
Trialists, C.1
Turnbull, F.2
Neal, B.3
Pfeffer, M.4
Kostis, J.5
Algert, C.6
Woodward, M.7
Chalmers, J.8
Zanchetti, A.9
MacMahon, S.10
-
43
-
-
79958709841
-
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: A meta-analysis
-
Huang G, Xu JB, Liu JX, He Y, Nie XL, Li Q, Hu YM, Zhao SQ, Wang M, Zhang WY, Liu XR, Wu T, Arkin A, Zhang TJ. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis. Eur J Clin Invest 2011;41:719-733.
-
(2011)
Eur J Clin Invest
, vol.41
, pp. 719-733
-
-
Huang, G.1
Xu, J.B.2
Liu, J.X.3
He, Y.4
Nie, X.L.5
Li, Q.6
Hu, Y.M.7
Zhao, S.Q.8
Wang, M.9
Zhang, W.Y.10
Liu, X.R.11
Wu, T.12
Arkin, A.13
Zhang, T.J.14
-
44
-
-
79954933210
-
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: A meta-analysis of placebo-controlled clinical trials
-
Tocci G, Paneni F, Palano F, Sciarretta S, Ferrucci A, Kurtz T, Mancia G, Volpe M. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am J Hypertens 2011;24:582-590.
-
(2011)
Am J Hypertens
, vol.24
, pp. 582-590
-
-
Tocci, G.1
Paneni, F.2
Palano, F.3
Sciarretta, S.4
Ferrucci, A.5
Kurtz, T.6
Mancia, G.7
Volpe, M.8
-
45
-
-
7444237666
-
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
-
Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to T, Enalapril Study G. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-1961.
-
(2004)
N Engl J Med
, vol.351
, pp. 1952-1961
-
-
Barnett, A.H.1
Bain, S.C.2
Bouter, P.3
Karlberg, B.4
Madsbad, S.5
Jervell, J.6
Mustonen, J.7
-
46
-
-
61849163580
-
EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries
-
Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, Group ES. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-137.
-
(2009)
Eur J Cardiovasc Prev Rehabil
, vol.16
, pp. 121-137
-
-
Kotseva, K.1
Wood, D.2
De Backer, G.3
De Bacquer, D.4
Pyorala, K.5
Keil, U.6
Group, E.S.7
|